Linked Life Data

10677817

Source:http://linkedlifedata.com/resource/pubmed/id/10677817

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2000-3-28
pubmed:abstractText
Pharmacokinetics and urinary excretion of the new fluoroquinolone antibacterial agent DW116 [1-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-1-piperazynyl)-1, 4-dihydro-4-oxoquinolone-3-carboxylic acid, hydrochloride] following oral administration (200, 400, 600 mg) were studied in humans as a phase I study. The plasma concentration of DW116 declined monoexponentially with a half-life range of 16-22 hr. The area under the curve (AUC) and Cmax increased proportionally as the dose increased. The T1/2 and mean residence time (MRT) (28.3-30.9 hr) were independent of dose. The Tmax appeared within 3 hr (0.9-2.7 hr) after drug administration. The Ka ranged from 1.3 to 4.1 (hr-1). The plasma half-life was much longer, and Cmax was higher by about two- to three-fold than conventional fluoroquinolones. Urinary recovery of DW116 was 29.6-61.6% of the dose. The maximum excretion rate appeared within 4 hr and decreased continuously after drug administration. A urinary metabolite was not detected in the urine extract obtained before and after hydrolysis by beta-glucuronidase (from Escherichia coli); this was different from other fluoroquinolone antibacterial agents. Poor metabolism in the kidney may contribute to the good oral bioavailability, but due to the low recovery (< 60%) in urine, it is possible that DW116 is metabolized in the liver or other organs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0363-9045
pubmed:author
pubmed:issnType
Print
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
103-6
pubmed:dateRevised
2008-7-23
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Pharmacokinetics and urinary excretion of DW116, a new fluoroquinolone antibacterial agent, in humans as a phase I study.
pubmed:affiliation
Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology, Seoul, Korea.
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase I